Evaluation of ROTARIX<sup>®</sup> Booster Dose Vaccination at 9 Months for Safety and Enhanced Anti-Rotavirus Immunity in Zambian Children: A Randomised Controlled Trial

Evaluation of ROTARIX<sup>®</sup> Booster Dose Vaccination at 9 Months for Safety and Enhanced Anti-Rotavirus Immunity in Zambian Children: A Randomised Controlled Trial

Oral rotavirus vaccines show diminished immunogenicity in low-resource settings where rotavirus burden is highest. This study assessed the safety and immune boosting effect of a third dose of oral ROTARIX<sup>®</sup> (GlaxoSmithKline) vaccine administered at 9 months of age. A total of 2...

Full description

Bibliographic Details
Main Authors: Natasha Makabilo Laban, Samuel Bosomprah, Michelo Simuyandi, Mwelwa Chibuye, Adriace Chauwa, Masuzyo Chirwa-Chobe, Nsofwa Sukwa, Chikumbutso Chipeta, Rachel Velu, Katanekwa Njekwa, Cynthia Mubanga, Innocent Mwape, Martin Rhys Goodier, Roma Chilengi
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Vaccines
Subjects:
rotavirus
ROTARIX<sup>®</sup>
vaccine
safety
booster dose
immunogenicity
Online Access:https://www.mdpi.com/2076-393X/11/2/346

Internet

https://www.mdpi.com/2076-393X/11/2/346

Similar Items